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TEMPORAL PROFILE OF MICROGLIAL ACTIVATION
A potential target of NSAIDs is thought to be the microglia 
  associated with the senile plaques. This is supported by a study by 
Mackenzie and Munoz (1998) showing in non-demented patients 
that those treated with NSAIDs had three times less activated 
microglia as non-treated controls. These data have been conﬁ  rmed 
by in vivo treatment with NSAIDs in mouse models of AD, which 
have shown decreases in microglial activation and in inﬂ  amma-
tory mediators such as iNOS, COX and cytokines (Lim et al., 2000; 
Heneka et al., 2005). Experiments carried out in cultured microglia 
have revealed that incubation with NSAIDs decreased the secretion 
of pro-inﬂ  ammatory cytokines and may increase Aβ phagocytosis 
(Lleo et al., 2007). However, the reduction of activated microglia 
and astroglia by NSAIDs was not signiﬁ  cant in AD patients, indicat-
ing an age or stage dependent difference in the glial response i.e. in 
their activation rate (Alafuzoff et al., 2000). Recently, these ﬁ  ndings 
have been backed up by observations indicating that microglia may 
change from alternative to classical phenotype over time (Colton 
et al., 2006; Hickman et al., 2008; Jimenez et al., 2008; Lucin and 
Wyss-Coray, 2009), although probably there is a heterogeneous 
population. In addition, a paper of Meyer-Luehmann et al. (2008) 
using two-photon microscopy showed that microglia in the aged 
mouse brain is less motile and posses fewer processes. Therefore, 
the response of NSAIDs may differ in “young” vs “old” microglia 
(Figure 1).
It has been hypothesized that early microglial activation in AD 
delays disease progression by promoting clearance of Aβ before 
formation of senile plaques. It is conceivable that glial activation 
is protective through mechanisms such as phagocytosis and clear-
ance of Aβ deposits (through release of insulin degrading enzyme, 
IDE), forming a protective barrier between Aβ and neurons and 
Many inﬂ  ammatory pathways have been implicated in Alzheimer’s 
disease (AD), yet these pathways are not sufﬁ  ciently well delineated 
to deﬁ  ne those processes and targets that may be pathogenic as 
opposed to those that may be protective. A clearer understand-
ing of these distinctions is critical to the design of therapeutic 
strategies. The ﬁ  nding that treatment with non-steroidal anti-
inﬂ  ammatory drugs (NSAIDs) is associated with a reduced risk 
and age of onset of AD reinforces the hypothesis that modulat-
ing inﬂ  ammation could have therapeutic efﬁ  cacy. The beneﬁ  cial 
effects of NSAIDs have also been associated with reductions in Aβ 
generation, since experiments in vitro and in AD animal models 
indicate that certain NSAIDs are able to decrease Aβ levels, plaque 
size and tau phosphorylation (Yoshiyama et al., 2007; El Khoury 
and Luster, 2008).
However, clinical trials have failed to reproduce the beneﬁ  cial 
effects of NSAIDs in AD patients. This has led to further analy-
sis of the previously published epidemiological data, which has 
revealed that the use of NSAIDs prevents cognitive decline in 
older adults if started in midlife (prior to age 65) rather than 
late in life (Hayden et al., 2007). In addition, it was recently 
shown that while NSAIDs may indeed protect those with health-
ier brains, they can accelerate AD pathogenesis in patients with 
advanced stages of the disease (Breitner et al., 2009). This is 
supported by studies in transgenic mice, in which NSAIDs can 
prevent the appearance of cell cycle protein markers in neurons 
in young mice, but not after cell cycle entry has been initiated 
(Varvel et al., 2009). Therefore, it seems that the protective effects 
of NSAIDs depend very much on the stage of the disease at which 
the medication is started as well as the duration of the treatment. 
Here we discuss four possible reasons why clinical trials with 
NSAIDs have been unsuccessful.
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2008) and may become detrimental through the release of cytokines 
and chemokines including IL-1β, IL-6, TNFα, IL-8 and MIP-1α 
(Hickman et al., 2008). These inﬂ  ammatory mediators modulate 
immune and inﬂ  ammatory function and may also alter neuronal 
secretion of growth factors, early in the disease (Wyss-Coray et al., 
2003; Maragakis et al., 2006; Wyss-Coray, 2006). In later stages, with 
persistent production of pro-inﬂ  ammatory cytokines, microglia 
lose their protective effect (Hickman et al., 2008; Jimenez et al., 
FIGURE 1 | Different targets for NSAIDs. The response to NSAIDs may differ 
depending on whether they are used in early stages of disease, in which 
microglia present an alternatively activated phenotype compared with late 
stages which is associated with a classical microglia phenotype. On the other 
hand, different subsets of NSAIDs have different afﬁ  nity for targets such as 
COX1, COX2, NFκB, PPARγ or γ-secretase, resulting in a range of effects 
including reductions in inﬂ  ammatory mediators, such as cytokines and 
alterations in Aβ generation.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 20  |  3
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shown to decrease the levels of secreted Aβ42 in cells as well as in 
animal models of AD (Weggen et al., 2001; Eriksen et al., 2003). 
Importantly, the generation of Aβ40 was largely unaltered by these 
compounds, indicating that certain NSAIDs modulate rather than 
inhibit γ-secretase activity (Czirr and Weggen, 2006). In fact, NSAIDs 
seem to bind APP, instead of the γ-secretase (Kukar et al., 2008). 
Some positive effects on cognitive performance of AD patients 
have been observed with indomethacin and the (R)-enantiomer of 
ﬂ  urbiprofen in phase-2 trials, while other NSAIDs without Aβ42 
reducing activity did not show beneﬁ  cial effects. However, recent 
clinical trials in mild AD cases revealed that R-ﬂ  urbiprofen (taren-
ﬂ  urbil) does not slow cognitive decline or the loss of activities of 
daily living (Green et al., 2009). In addition, epidemiological studies 
report that the protective effect of NSAIDs seems to be independent 
of the Aβ42 reducing activity of the NSAID (Szekely et al., 2008a; 
Vlad et al., 2008).
Besides targeting molecules such as COX and γ-secretase, some 
NSAIDs such as ibuprofen, naproxen and indomethacin can acti-
vate PPARγ (Jaradat et al., 2001). PPARγ inhibition regulates the 
transcription of pro-inﬂ  ammatory genes, such as IL1β; therefore 
activation of PPARγ consequently inhibits the inﬂ  ammatory 
response. In addition, we found that PPARγ activators are able to 
decrease total Aβ levels under inﬂ  ammatory conditions by affecting 
BACE1 transcription (Sastre et al., 2006b, 2008). Recently it was 
shown that ibuprofen is able to suppress RhoA activity in neuronal 
cells through PPARγ activation, promoting neurite elongation (Dill 
et al., 2010). Therefore, PPARγ activation could be beneﬁ  cial in AD 
at several levels. A recent prospective randomized, open-controlled 
study with pioglitazone (a typical PPARγ agonist) has shown that 
at 6 months the WMS-R logical memory-I scores signiﬁ  cantly 
increased in the pioglitazone group, but not in the control group 
(Hanyu et al., 2009). Another PPARγ agonist, rosiglitazone has been 
trialed with inconsistent results. In contrast to pioglitazone, rosigli-
tazone cannot cross the blood brain barrier (BBB) (Festuccia et al., 
2008) and it was suggested that the protective effects are mediated 
through its effects on insulin and glucocorticoids that are able to 
penetrate into the brain.
Certain NSAIDs, such as ﬂ  urbiprofen and indomethacin, inhibit 
the nuclear translocation of the transcription factor NF-kB. In 
addition, it was recently shown that R-ﬂ  urbiprofen can interfere 
with the interaction between RXRα and 9-cis-retinoid acid, and 
that 9-cis-retinoid acid decreases (R)-ﬂ  urbiprofen’s reduction of 
Aβ secretion (You et al., 2009). R-ﬂ  urbiprofen has been shown to 
upregulate NGF and BDNF in vitro, which could potentially offer 
neuroprotection (Zhao et al., 2008). However, as mentioned above, 
R-ﬂ  urbiprofen trials have not been successful, perhaps because of 
its low permeability into the brain and its weak pharmacological 
activity (Imbimbo, 2009).
DURATION AND DOSE
The duration of the treatment could also inﬂ  uence the magni-
tude of the effect. A meta-analysis of nine studies revealed that 
the beneﬁ  t of the NSAID treatment was greater in long-term users 
than in intermediate users (Etminan et al., 2003). Moreover, it has 
been suggested that at least 2 years of exposure are necessary to 
obtain full beneﬁ  t, so the beneﬁ  ts may be greater the longer NSAIDs 
are used (Sastre et al., 2006a). The effect of NSAIDs in mice has 
function. In addition, microglia from old transgenic mice have a 
decrease in the expression of the Aβ-binding scavenger receptors A 
(SRA), CD36 and RAGE, and the Aβ degrading enzymes IDE, nepri-
lysin and MMP9, compared with wild-type controls (Hickman 
et al., 2008) (Figure 1). On the other hand, in aged human brain 
many microglia are dystrophic showing morphological features 
indicative of senescence, such as fragmented cytoplasmic proc-
esses (Streit et al., 2004). Therefore, overactivated and dysregulated 
microglia could cause uncontrolled inﬂ  ammation that may drive 
the chronic progression of AD (Mrak and Grifﬁ  n, 2005; Gao and 
Hong, 2008).
Microglia can be primed or desensitized by a stimulus (such as 
Aβ), which prepares the cells for an enhanced or decreased response 
to a second challenge (Gao and Hong, 2008). Microglia in aged or 
diseased brains are primed and usually behave differently to those 
in younger individuals (Gao and Hong, 2008). Thus, it is likely that 
microglia do not respond equally to anti-inﬂ  ammatory therapy 
in old age and therefore, treatment of patients with NSAIDs in 
advanced stages of the disease may not produce any beneﬁ  t.
One of the most controversial points is to establish whether 
microglia are “oversaturated” at a certain age or whether there is 
a loss of function. The debate on microglia function in AD pro-
gression has been intensiﬁ  ed by a recent report showing that AD 
animal models with nearly complete ablation of microglia did not 
display differences in plaque formation (Grathwohl et al., 2009), 
raising questions as to whether inﬂ  ammation may have an effect 
on neurodegeneration and cognitive decline rather than a direct 
role on Aβ deposition. Furthermore, a study using two-photon 
microscopy in the intact brain of living AD mice has revealed an 
involvement of microglia in neuron elimination, indicated by locally 
increased number and migration velocity of microglia around lost 
neurons (Fuhrmann et al., 2010). Therefore, evidence has started 
to accumulate that the function of microglia is neuroprotection in 
young individuals (by secretion of neurotrophic factors and anti-
 inﬂ  ammatory cytokines) and that “senescent” microglia contribute 
to the onset of sporadic AD (Streit et al., 2004, 2009).
Similarly, there are other factors that may change the risk for AD 
depending on the age, such as obesity or body mass index (BMI), 
which is an important predictor for late life dementia. However, 
in late life, low and declining BMI is associated with increased 
AD risk. Therefore, there is time frame for the beneﬁ  cial effect of 
certain factors, and since AD is a disease with a long preclinical 
period, trials of short duration in severe cases of AD do not provide 
reliable information regarding development of AD (Bennett and 
Whitmer, 2009).
MULTIPLE MOLECULAR TARGETS FOR NSAIDs
The type of NSAID appears to affect the outcome of the clinical 
trial (Figure 1). The inhibition of the canonical targets of NSAIDs, 
cyclooxygenase-1 and -2 (COX-1 and COX-2), do not seem to be 
responsible for the protective effect of NSAIDs in AD (see review 
Lleo et al., 2007). On the contrary, some COX-2 inhibitors may 
raise Aβ1-42 secretion (Kukar et al., 2005).
Interestingly, some NSAIDs and other small organic molecules 
have been found to modulate γ-secretase and to selectively reduce 
Aβ1-42 levels without affecting Notch cleavage. A subset of NSAIDs 
including ibuprofen, sulidac sulﬁ  de, and indomethacin have been Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 20  |  4
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2009). Similar positive effects in ApoE4 carriers have also been 
seen when the NSAIDs have been taken in conjunction with Vit E 
(Fotuhia et al., 2008). In addition, the inﬂ  uence of NSAID use in 
microglia activation has been noted in all ApoE genotypes however 
the trend of lower counts of glial cells with regular NSAID use was 
more marked in patients carrying the ApoEε4/4 alleles (Alafuzoff 
et al., 2000).
By contrast, results from clinical trials with rosiglitazone suggest 
that those without an APOE ε4 allele exhibit cognitive and func-
tional improvement in response to rosiglitazone, while those that do 
carry the allele carriers showed no improvement and some decline 
was noted (Risner et al., 2006). ApoE4 and C-terminal-truncated 
fragments of apoE4 [apoE4(1–272), lacking the C-terminal 27 aa] 
impair cytoskeletal structure and mitochondrial function and its 
seems that rosiglitazone reverses this effect.
CONCLUSIONS
There is still controversy regarding the reasons why clinical tri-
als with NSAIDs have provided such disappointing results. Here 
we suggest that the short duration of the trials, the use of drugs 
targeting the wrong molecule, the wrong timing of the treatment 
(patients too old or too severely ill), the low levels of the drugs 
reaching the CNS and the genetic variability of the patients may 
all have contributed to the failures.
It is still unclear whether NSAIDs are beneﬁ  cial because of 
their effects on reducing Aβ or whether it is because of their anti-
 inﬂ  ammatory action or the interaction between both (reducing 
inﬂ  ammation may decrease Aβ generation and the other way 
around). It would be helpful in the future to determine whether 
patients involved in trials experience changes in biomarkers in 
blood or CSF (such as Aβ levels, tau or inﬂ  ammatory markers) 
and whether those correlate with cognitive performance.
Taking all the currently available evidence together, NSAIDs 
should be used as preventive treatment rather than a therapeutic 
option and this would make more sense in a disease with a long pre-
clinical period, with evidence that microglial/cytokine events take 
place years or even decades before plaques or tangles are detected 
(Grifﬁ  n et al., 1989; Cagnin et al., 2001).
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been reviewed extensively by Imbimbo (2009). Short term studies 
(3- to 7-days treatment) in transgenic mice revealed decreases in 
Aβ levels, particularly in the Aβ42 isoform and activated micro-
glia, although some studies have shown no changes, depending 
on the drug and the animal model (Eriksen et al., 2003; Heneka 
et al., 2005; Lanz et al., 2005). Long-term administration has dem-
onstrated protective effects predominantly using ibuprofen and 
indomethacin treatments, in both types of Aβ, as well as brain 
plaque load and inﬂ  ammation (see Imbimbo, 2009). However, 
chronic R-ﬂ  urbiprofen produced weak effects on Aβ deposition, 
and was more effective as a preventive rather than a therapeu-
tic treatment (Kukar et al., 2007). This is in line with the results 
obtained in clinical trials using ﬂ  urbiprofen.
The dose and permeability of the drug could be relevant, although 
some epidemiological studies suggest that the daily dose is not 
important. In’t Veld et al. (2001) noted that low doses had effects 
equal to those of the higher doses typically prescribed for osteoar-
thritis and other inﬂ  ammatory conditions. However, the failure of 
some clinical trials has been associated with the low permeability 
of certain drugs such as R-ﬂ  urbiprofen and rosiglitazone. In addi-
tion, there is some conﬂ  ict between the potency of certain NSAIDs 
to decrease Aβ42 in vitro (reaching 300 µM) and the effective drug 
concentration in the brain. Active concentrations of NSAIDs found 
in human plasma and cerebrospinal ﬂ  uid are in the lower µM range 
(Bannwarth et al., 1990, 1995), which could not account for the 
effects on γ-secretase cleavage. Unfortunately, the clinical dose is 
limited because of adverse effects such as irritation and ulceration 
of the gastro-intestinal (GI) mucosa. There is growing interest in 
improving absorption and BBB permeability of certain NSAIDs 
in order to allow the administration of lower doses of these drugs. 
Another point that has to be borne in mind is that the barrier may 
be compromised in neurodegenerative diseases, permitting the dif-
fusion of molecules that usually have no access to the brain paren-
chyma, therefore the dose reaching the brain can be different in AD 
patients compared with healthy controls (Nguyen et al., 2002).
ApoE GENOTYPE
Another possible confounding factor in NSAID trials is the geno-
type of the patients being treated, most notably in relation to ApoE. 
The majority of prospective studies appear to show greater beneﬁ  ts 
in those with an ApoE ε4 allele (Hayden et al., 2007; Szekely et al., 
2008b). In a recent trial, the ApoE ε4 carriers treated with ibuprofen 
were the only group without cognitive decline (Pasqualetti et al., Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 20  |  5
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